NasdaqGS:ATRI

Stock Analysis Report

Executive Summary

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide.


Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Atrion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.2%

ATRI

0.5%

US Medical Equipment

0.06%

US Market


1 Year Return

-16.7%

ATRI

20.6%

US Medical Equipment

19.4%

US Market

Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 20.6% over the past year.

Return vs Market: ATRI underperformed the US Market which returned 19.4% over the past year.


Shareholder returns

ATRIIndustryMarket
7 Day-2.2%0.5%0.06%
30 Day-5.7%0.1%1.1%
90 Day-7.1%7.5%8.9%
1 Year-16.1%-16.7%21.6%20.6%21.9%19.4%
3 Year38.9%35.8%81.5%76.4%48.9%39.3%
5 Year116.4%107.8%114.9%92.3%71.9%53.1%

Price Volatility Vs. Market

How volatile is Atrion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atrion undervalued compared to its fair value and its price relative to the market?

33.93x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ATRI ($667) is trading above our estimate of fair value ($344.39)

Significantly Below Fair Value: ATRI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ATRI is good value based on its PE Ratio (33.9x) compared to the Medical Equipment industry average (46.8x).

PE vs Market: ATRI is poor value based on its PE Ratio (33.9x) compared to the US market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRI is overvalued based on its PB Ratio (5.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Atrion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Atrion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Atrion performed over the past 5 years?

6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRI has high quality earnings.

Growing Profit Margin: ATRI's current net profit margins (23.4%) are higher than last year (23.2%).


Past Earnings Growth Analysis

Earnings Trend: ATRI's earnings have grown by 6.4% per year over the past 5 years.

Accelerating Growth: ATRI's earnings growth over the past year (3.7%) is below its 5-year average (6.4% per year).

Earnings vs Industry: ATRI earnings growth over the past year (3.7%) underperformed the Medical Equipment industry 7.1%.


Return on Equity

High ROE: ATRI's Return on Equity (15.7%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Atrion's financial position?


Financial Position Analysis

Short Term Liabilities: ATRI's short term assets ($144.8M) exceed its short term liabilities ($11.4M).

Long Term Liabilities: ATRI's short term assets ($144.8M) exceed its long term liabilities ($13.1M).


Debt to Equity History and Analysis

Debt Level: ATRI is debt free.

Reducing Debt: ATRI has not had any debt for past 5 years.

Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: ATRI has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ATRI's debt is covered by short term assets.


Next Steps

Dividend

What is Atrion's current dividend yield, its reliability and sustainability?

0.93%

Current Dividend Yield


Dividend Yield vs Market

company0.9%marketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: ATRI's dividend (0.93%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).

High Dividend: ATRI's dividend (0.93%) is low compared to the top 25% of dividend payers in the US market (3.7%).


Stability and Growth of Payments

Stable Dividend: ATRI's dividends per share have been stable in the past 10 years.

Growing Dividend: ATRI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (28.5%), ATRI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

22.1yrs

Average board tenure


CEO

David Battat (49yo)

8.8yrs

Tenure

US$1,543,530

Compensation

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD1.54M) is below average for companies of similar size in the US market ($USD3.81M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Emile Battat
Executive Chairman22.1yrsUS$665.27k8.02% $101.7m
Hugh Morgan
Independent Director32.1yrsUS$132.00k0.91% $11.6m
John Stupp
Independent Director35.1yrsUS$140.22k1.52% $19.3m
Ronald Spaulding
Independent Director14yrsUS$130.00k0.11% $1.5m
Preston Athey
Independent Director2.9yrsUS$126.00k0.022% $274.8k

22.1yrs

Average Tenure

70yo

Average Age

Experienced Board: ATRI's board of directors are seasoned and experienced ( 22.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATRI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Atrion Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atrion Corporation
  • Ticker: ATRI
  • Exchange: NasdaqGS
  • Founded: 1944
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.268b
  • Shares outstanding: 1.85m
  • Website: https://www.atrioncorp.com

Number of Employees


Location

  • Atrion Corporation
  • One Allentown Parkway
  • Allen
  • Texas
  • 75002
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 1969

Biography

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company’s cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/18 23:40
End of Day Share Price2020/02/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.